TPST-1495 is under clinical development by Tempest Therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TPST-1495’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData


Data Insights N

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TPST-1495 overview

TPST-1495 is under development for the treatment of microsatellite-stable colorectal cancer (MSS CRC), non-small cell lung cancer (NSCLC), urothelial cancer, endometrial cancer, adenocarcinoma of the gastroesophageal junction, squamous cell carcinoma of the head and neck (SCCHN), bladder cancer, gastric cancer and familial adenomatous polyposis. It is administered orally. The drug candidate acts by targeting prostaglandin receptor EP2 and EP4.

Tempest Therapeutics overview

Tempest Therapeutics (Tempest), formerly Millendo Therapeutics, Inc. is a biotechnology company. It develops small molecule medicines that regulate anti-tumor immunity pathways. The company’s pipeline portfolio includes TPST-1495, an IDO (enzyme) inhibitor that generates kynurenine, a powerful immunosuppressive factor, which regulates immune cells in the tumor microenvironment (TME) and blocks anti-tumor immunity; TPST-1120, an antagonist that acts against peroxisome proliferator-activated receptor alpha (PPARa); and E-prostanoid (EP) receptor antagonists whose prostaglandin E2 (PGE2) pathway facilitates immune suppression in the TME. Tempest develops an orally available inhibitor of TREX-1 designed to activate cGAS/STING pathway, for the development of anti-tumor immunity. TempestTx is headquartered in Brisbane, California, the US.

For a complete picture of TPST-1495’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.